INNOCRIN PHARMACEUTICALS

Innocrin discovers and develops novel oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of prostate cancer. The company offers CYP17 lyase, a validated enzyme target for the treatment of CRPC and other hormonally-driven conditions, such as breast cancer, endometriosis, or congenital adrenal hyperlplasia. Its product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth–androgen biosynthesis and AR transcriptional signaling.

#SimilarOrganizations #People #Financial #Website #More

INNOCRIN PHARMACEUTICALS

Social Links:

Linkedin

Industry:

Biotechnology Health Care Medical Pharmaceutical

Founded:

2004-01-01

Address:

Durham, North Carolina, United States

Country:

United States

Website Url:

http://www.innocrinpharma.com

Total Employee:

11+

Status:

Active

Contact:

(919) 467-8539

Total Funding:

36 M USD

Technology used in webpage:

SPF Google Tag Manager OVH ComScore MapQuest

Similar Organizations

bionpharma-logo

BionPharma

BionPharma develops and commercializes affordable quality generics and builds strong and effective partnerships.

nuchem-sciences-logo

NuChem Sciences

NuChem Sciences is a drug discovery in chemistry contract research organization (CRO) located in Montréal and Lévis.

pantheryx-logo

PanTheryx

PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.

Founder

bill-moore_image

Bill Moore

Investors List

eshelman-ventures_image

Eshelman Ventures

Eshelman Ventures investment in Series D - Innocrin Pharmaceuticals

Official Site Inspections

http://www.innocrinpharma.com

Host Informations
Whois Informations

Loading ...

More informations about "Innocrin Pharmaceuticals" on Search Engine